Bruce Leander, vice president and general manager of Applied Biosystems subsidiary Ambion, has retired, an ABI official confirmed.
Leander served as president of Ambion from 1998 until the company was acquired by ABI in early 2006 (see RNAi News, 1/5/2006).
William Marshall has stepped down from his role as vice president of technology and development for Dharmacon parent firm Thermo Fisher Scientific, a Thermo Fisher Scientific official has confirmed.
Marshall served as executive vice president of research and operations and site manager at Dharmacon after its 2004 acquisition by Fisher Scientific (see RNAi News, 2/13/2004) and before Fisher Scientific merged with Thermo Electron.
He is now president and CEO of microRNA therapeutics startup Miragen Therapeutics.
Rosetta Genomics said this week that it has named Ronen Tamir as the company’s executive vice president of marketing and communications.
Tamir was previously vice president of investor relations for North America at Novartis. Before that, he held several positions at Serono. He holds an MBA from Warwick Business School.
Regulus Therapeutics, a microRNA drugs joint venture between Isis Pharmaceuticals and Alnylam Pharmaceuticals (see RNAi News, 9/13/2007), said this week that it has named Kleanthis Xanthopoulos as president and CEO.
Before joining Regulus, Xanthopoulos was a managing director of Enterprise Partners Venture Capital. Before that, he co-founded and served as president and CEO of Anadys Pharmaceuticals.
Xanthopoulos has also held various positions at Aurora Biosciences. He holds a BSc in biology from Aristotle University and an MSc and PhD in molecular biology from the University of Stockholm.